新加良附方对移植性人胃癌抑制效应研究  

Inhibitory effect of Xinjialiangfu Formula on transplantation human gastric cancer

作　　者：董青[1] 李春[2] 马成杰[1] 陈信义[1] 

机构地区：[1]北京中医药大学东直门医院肿瘤血液科,北京100700 [2]中国医学科学院肿瘤研究所

出　　处：《北京中医药大学学报（中医临床版）》2008年第1期14-16,共3页Journal of Beijing University of Traditional Chinese Medicine

摘　　要：目的观察新加良附方对移植性人胃癌抑制效应。方法人源胃癌细胞系(BGC-823)经传代培养后,通过BALB/C-nu裸鼠移植制造肿瘤模型,以5-氟尿嘧啶和不同剂量的新加良附方浸膏进行干预性治疗,用抑瘤率评价新加良附方对BGC-823移植瘤生长的抑制作用。结果5-氟尿嘧啶组及新加良附方大、中、小剂量组的肿瘤抑制率分别为54.2%、54.3%、36.8%和23.3%;5-氟尿嘧啶组及新加良附方大剂量组与模型组瘤重比较,有统计学意义(P<0.05)。结论新加良附方大剂量组对BGC-823有明显抑制作用。Objective To observe the inhibitory effect of Xinjialiangfu Formula on transplantation human gastric cancer. Methods After culturing and propagating BGC-823 of human gastric cancer was implanted to BALB/C-nu mice to establish the tumor model, which then was treated interferingly with 5-fluorouracil （5-FU） and different doses of Xinjialiangfu Formula. The inhibitory effect of Xinjialiangfu Formula on BGC-823 was evaluated by the tumor inhibitory rate. Results The tumor inhibitory rates of 5-FU group and different-dose Xinjialiangfu Formula groups were respectively 54.2 %, 54.3 %, 36.8 % and 23.3 %. The comparison between the model group and 5-FU group or high-dose Xinjialiangfu Formula group in tumor weight was significant statistically （P〈0.05）. Conclusion High-dose of Xinjialiangfu Formula has a significant inhibitory effect on BGC-823 of human gastric cancer.

关 键 词：新加良附方 人胃癌细胞系 肿瘤抑制率 

分 类 号：R273[医药卫生—中西医结合]